Bay Bridge Boat Show Announces Expanded Format
The Annapolis Boat Shows is set to combine their two spring shows into one expanded 2021 Bay Bridge Boat Show. From April 15-18, the Bay Bridge Marina in Stevensville, Md will host the largest, in-water power and sailboat show in the Mid-Atlantic. Attendees will have the opportunity to climb aboard hundreds of boats, both power and sail, as well as shop the latest in marine gear, equipment, and accessories. An exciting number of educational opportunities and on-board activities will also be offered for all boaters to experience.
13th Annual Bridges to the World International Film Festival
The World Artists Experiences film festival features five films from five countries. It will run for five weeks on Tuesdays at 7:00 p.m., Eastern Time, beginning February 2 and ending March 2. The second film is “Mellow Mud” from Latvia., produced in 2016 . Es esmu šeit (which translates as “I am here”) presents a bittersweet story of a young woman coming of age under extraordinarily difficult circumstances. Not only does she seek to establish a mature self-identity, but to also assert her value and independence in a world that has ignored her — to exclaim “I am here.”
Zoom Webinar ID: 833 6029 3896
Passcode: Bridges
The Zoom link: https://us02web.zoom.us/j/83360293896?pwd=dCtRbTB3RENBNzBxanA2NFFCV3pRZz09
Xeljanz, Xeljanz XR (tofacitinib): Drug Safety Communication - Initial Safety Trial Results Find Increased Risk of Serious Heart-related Problems and Cancer with Arthritis and Ulcerative Colitis Medicine
The FDA is alerting the public that preliminary results from a safety clinical trial show an increased risk of serious heart-related problems and cancer with the arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib) compared to another type of medicine called tumor necrosis factor (TNF) inhibitors. FDA required the safety trial, which also investigated other potential risks including blood clots in the lungs and death. Those final results are not yet available. In February 2019 and July 2019, FDA warned that interim trial results showed an increased risk of blood clots and death with the higher 10 mg twice daily dosage, and as a result, approved a Boxed Warning to the tofacitinib prescribing information. The clinical trial is now complete and initial results show a higher occurrence of serious heart-related events and cancer in rheumatoid arthritis (RA) patients treated with both doses of tofacitinib compared to patients treated with a TNF inhibitor. FDA is awaiting additional results from the trial. For more information, click here.
